Innovation Pharmaceuticals Inc (IPIX)

[cabel]

Sept. 9 PR..."Cellceutix will not know the actual cure rates per treatment arm until the data is unblinded in October/November. However, the Company is very optimistic and views the high average cure rate on the blinded data as a very good sign for Brilacidin. Assuming positive results after unblinding, Cellceutix will have proven that Brilacidin is a safe and effective drug in the Phase 2 trial, and all activities will be triggered for initiation of a pivotal Phase 3 trial."

I would think as soon as it is UNBLINDED (probabaly 1st week in Oct) Leo and Dr Menon can look at the data,.. but before annoucning anything like the Top-Line data,... a preliminary analysis must be done first (end of Oct, beg of Nov).

But I would think they could superficially see what the results would be at UNBLINDING,.. but will not announce anything except perhaps that it was unblinded.